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Abstract  
Objective: To investigate the effectiveness of high-voltage monophasic 
pulsed current (HVMPC) as an adjunct to a standard wound care for the 
treatment of Stage II and III pressure ulcers (PrUs).  
Design: Prospective, randomized, double-blind, controlled clinical study.  
Setting: Two nursing and care centers.  
Patients: Patients with PrUs that did not respond to previous treatment for 
at least 4 weeks were randomly assigned to the electrical stimulation (ES) 
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group (25 patients; mean age of 79.92 ± 8.50 years; mean wound surface 
area [WSA] of 10.58 ± 10.57 cm2) or to the control group (24 patients; 
mean age of 76.33 ± 12.74 years; mean WSA of 9.71 ± 6.70 cm2).  
Interventions: Both the ES and control groups received standard wound 
care and respectively, cathodal HVMPC (154 microseconds; 100 pulses per 
second; 0.24 A; 250 µ/s) applied continuously for 50 minutes once a day, 5 
times a week, or sham HVMPC.  
Main Outcome: Percentage area reduction over 6 weeks of intervention.  
Main Results: In the ES group, there was a statistically significant decrease 
in WSA after 1 week of treatment (35% ± 30.5%) compared with 17.07% ± 
34.13% in the control group (P = .032). After treatment, at week 6, 
percentage area reduction in the ES group was 80.31% ± 29.02% versus 
54.65% ± 42.65% in the control group (P = .046).  
Conclusions: Cathodal HVMPC reduces the WSA of Stage II and III PrUs. 
The results are consistent with the results of other researchers who used 
HVMPC to treat PrUs.  
Keywords: high-voltage monophasic pulsed current wound healing; 
pressure ulcers; electrical stimulation  
Introduction  
Pressure ulcers (PrUs) are a clinical problem for patients and 
medical personnel all over the world. The treatment of PrUs is, in 
most cases, a long process involving the application of various 
frequently costly interventions. It is therefore important to develop 
new methods that effectively promote and accelerate the healing of 
these intractable wounds. One of the methods used to treat PrUs is 
electrical stimulation (ES), which is recommended by the clinical 
practice guidelines as appropriate for treating chronic Stage II, III, 
and IV PrUs.1,2  
 
The Evidence Supporting Electrical Stimulation 
for Wound Healing  
The authors of meta-analyses and reviews published in recent 
years point to the positive effect of ES on the healing of chronic 
wounds.3–5 The systematic review of 174 studies (randomized trials 
and comparative observational studies) on different PrU treatment 
strategies in adults that Smith et al.3 performed in 2013 showed 
moderately consistent results from 1 good-quality and 8 fair-quality 
trials, each of which presented ES as a biophysical energy capable of 
improving PrU healing rates. In the same year, Thalkral et al.4 
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reviewed 16 randomized clinical trials (RCTs) in which ES was used to 
treat wounds. They concluded that ES decreased bacterial infection, 
increased local perfusion, and accelerated wound healing. It is also 
noteworthy that none of the available studies mentions device-related 
complications or adverse effects of the electric field energy. In 2014, 
Koel and Houghton5 systematically analyzed 15 ES studies with clear 
randomized controlled design and published their findings of healing 
rate expressed as percentage area reduction (PAR) over 4 weeks of 
treatment. They concluded that applying additional monophasic ES to 
a program of standard wound care (SWC) increases the reduction of 
PrU area in 4 weeks of treatment by an extra 42.7% (95% confidence 
interval, 32.0–53.3).  
Types Of Electrical Currents And Treatment 
Parameters  
The range of electric currents used in wound treatment 
research varies from low-intensity direct current6,7 (LIDC; <1.0 mA), 
microamperage current8–10 (very low current imitating natural current 
of injury applied at subsensory level9), low-voltage biphasic pulsed 
current (LVBPC),11–13 low-voltage monophasic pulsed current 
(LVMPC),14–19 and high-voltage monophasic pulsed current 
(HVMPC).20–27 In 2014, Houghton28 published a systematic review of 
32 clinical studies on LIDC, microamperage current, LVBPC, and 
LVMPC, and Polak et al.29 performed a critical review of 11 clinical 
studies on chronic wounds treated with HVMPC. Both authors28,29 
reported that ES protocols involving the use of LVBPC,28 LVMPC,28 and 
HVMPC29 were capable of producing consistently positive results in 
patients with chronic wounds. In the opinions of those authors,28,29 
the ES-induced improvement in wound healing depends on the type 
of ES waveform and the particular methodology used, but the optimal 
parameters of the stimulus and the ES schedule for chronic wounds 
still need to be defined.  
In the RCTs, monophasic HVMPC was used to treat venous leg 
ulcers (VLUs),22,24 PrUs,20,21,25–27 and diabetic foot ulcers (DFUs).23 In 
all of cited studies, HVMPC was applied for designated time periods 
with SWC (the latter intervention was necessary for ethical reasons). 
The results were compared with the effects of treatment in the control 
groups that respectively received only SWC22,25–27 or SWC and sham 
HVMPC.20,21,23,24 Authors of all cited studies indicated that HVMPC 
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promoted wound healing because the wound surface area (WSA) in 
the SWC + HVMPC groups decreased more than that in the control 
groups.20–27  
The parameters of HVMPC used in all cited studies were similar. 
The authors reported using twin-peak monophasic pulses20–27 with a 
pulse duration of 100 microseconds20,22–24,26,27 or 50 microseconds25 
and pulse frequency of typically 100 pulses per second (pps)21,22,24–29 
or 105 pps,20 at which the current evoked only submotor sensory 
perception.20–27 Electrical stimulation involving HVMPC was usually 
applied for a total of 3.75 to 7 hours a week.20–22,24,26,27 In most cases, 
treatment sessions of 45 to 60 minutes were held daily, 5 to 7 days a 
week.20–22,24,26,27 Both electrodes were placed on a conductive saline, 
moist gauze, or on a wafer hydrogel dressing. The treatment 
electrode was placed on the wound surface,20–27 and the return 
electrode was attached to healthy skin at least 15 to 20 cm away.20–
22,24,26,27  
The authors of the published studies used different treatment 
electrode polarities. In some cases, treatment started with cathodal 
stimulation that was continued over the whole length of the trial or 
was applied at the initial stage only. Griffin et al.21 and Houghton et 
al.24 had good results treating PrUs21 and VLUs24 using only the 
cathode. In the first of the 2 studies,21 Stage II through IV PrUs in the 
ES group (SWC + ES) demonstrated significantly greater percentage-
of-change decrease in WSA from their pretreatment size than did 
ulcers in the control group (SWC + sham ES) at days 5, 15, and 20 (P 
< .05).21  
In the second study,24 by week 4, WSA in the ES group (SWC + 
ES) decreased by 44.3% compared with only 16% in the control 
group (SWC + sham ES) with P < .05. In another study conducted by 
Houghton et al,25 PrUs (mostly Stage III and IV) were stimulated with 
the cathode in the first week, and then polarity was reversed every 
week until the end of the 12-week treatment period. Percentage area 
reduction of PrUs was evaluated at weeks 1, 2, and 3. There was 
significantly less WSA from baseline in the ES group (SWC + ES) than 
in the control group (SWC alone) at month 3 (P = .048). Franek et 
al.22,26 and Polak et al.27 too, started the treatment of VLUs22 and 
PrUs26,27 with cathodal stimulation that was continued for the first 1 to 
3 weeks depending on the growth of granulation tissue. When at least 
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50% of the wound surface was covered with granulation tissue, the 
anode was introduced as the treatment electrode until the end of 
treatment that lasted 6 weeks22,26 and 4 weeks,27 respectively. The 
authors of the first study22 reported that after 2 weeks of cathodal 
stimulation the granulation tissue area in VLUs was significantly 
greater (P < .003) in the ES group (SWC + ES) than in the control 
group (SWC alone) and that 6 weeks of treatment decreased the area 
of VLUs more in the ES group (the decrease was not significant, P 
> .05) than in the control group.22 The results obtained by the 
authors of the second study26 involving Stage II and III PrUs were 
slightly different. The ES group (SWC + ES) and the control group 
(SWC alone) were similar in the area of granulation tissue over the 
whole period of treatment (P > .05), but after 6 weeks of treatment, 
PAR in the ES group was greater than that in the control group (P 
= .00003).26 The authors of the third study27 (a preliminary trial with 
a sample of only 22 patients with Stage II and III PrUs) recorded that 
percentage decrease in PrU area after 4 weeks of treatment was 
significantly greater in the ES group (SWC + ES) than that in the 
control group (SWC alone) with P = .0079 (they did not record the 
area of granulation tissue). The methodology that Kloth and Feedar20 
followed to apply cathode and anode as the treatment electrodes was 
considerably different from the methodologies used in the presented 
studies. They stimulated Stage IV PrUs with the anode and reversed 
polarity to negative only if healing progress was not satisfactory. In 
the ES group (SWC + ES), WSA decreased at a mean rate of 44.8% a 
week and closed 100% over a mean period of 7.3 weeks. In the 
control group (SWC + sham ES), WSA decreased by an average of 
28.9% over an average period of 7.4 weeks. The different polarity of 
the treatment electrode used in the studies and slightly different 
results obtained by their authors suggest that more clinical research 
is needed to determine the wound healing efficacy of the cathode and 
the anode.  
Some progress has been made toward the creation of more 
reliable guidelines on the use of the 2 electrodes in treating wounds in 
humans. Having reviewed the results of in vitro and in vivo studies, 
Kloth and Zhao30 have concluded that both these electrodes promote 
wound healing and that the polarity of the treatment electrode should 
enhance the cellular needs during the inflammatory and proliferative 
phases of healing.  
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The authors of in vitro studies31,32 have reported that anodal 
stimulation facilitates electrotaxis of macrophages31 and neutrophilis32 
for autolysis and reactivation of the inflammatory phase of healing. 
Eberhardt et al.33 have demonstrated in vivo electrotaxis of 
neutrophils toward the anode. The efficacy of anodal stimulation in 
the early stages of wound healing has been recently confirmed from 
in vivo studies with animals.34,35 Talebi et al.34 studied in vivo the 
effect of anodal and cathodal ES (600 µA; 1 hour per day; 3 sessions 
a week for a period of 3 weeks) on injury potential and wound size in 
guinea pigs. They concluded34 that anodal ES was appropriate as a 
means of improving the healing of acute skin wounds, because it 
causes the wound surface to close and decreases healing time. The 
Borba et al.35 randomized in vivo study with rats showed that anodal 
stimulation (rectangular pulse current of 8 mA at a frequency of 7.7 
pps) improved neoangiogenesis in the early stage of acute 
experimental wound healing.  
Cathodal ES has been found to enhance the proliferative phase 
of wound healing. In vitro studies36–39 have demonstrated that in cell 
cultures, human fibroblasts,36–38 keratinocytes,36 and bovine corneal 
epithelial cells39 migrate directionally toward the cathode. The studies 
imply that cathodal stimulation promotes granulation tissue 
formation.36,38,40,41 The results of Bourguignon and Bourguignon’s41 in 
vitro study with human fibroblasts indicated that HVMPC (twin-spike 
pulses; 100 microseconds; 100 pps) could significantly increase the 
rate of protein and deoxyribonucleic acid synthesis. They observed 
that maximum synthesis of protein and deoxyribonucleic acid 
occurred at 50 and 75 V in cells located adjacent to the negative 
electrode. According to Zhao et al.39 the negative electrode can 
effectively stimulate the epithelialization of wounds.  
Asadi et al.42 found from in vivo research that cathodal sensory-
level ES increases the release of vascular endothelial growth factor 
(VEGF) in skin. Their study was designed to evaluate the effect of 
sensory (LIDC; 600 µA) and motor (monophasic current; pulse 
duration 300 microseconds, 100 pps, 2.5–3.0 mA) cathodal ES on 
VEGF release in muscle and skin in the wound site in 48 male 
Sprague-Dawley rats randomly assigned to 2 experimental groups 
and a control group (ES was not applied). A full-thickness skin incision 
was made on each animal’s dorsal region. The experimental groups 
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received ES for 1 hour for 3 or 7 days. The VEGF expression in muscle 
and skin was measured on days 3 and 7 after surgical incision. On 
day 3, VEGF levels did not differ among the groups. On day 7, the 
periwound cutaneous VEGF levels were significantly higher in the 
sensory-level stimulation group than in the other groups (P < .05). 
No differences in VEGF were found in muscle tissue. These results led 
Asadi et al.42 to conclude that the sensory-level cathodal ES increases 
the release of VEGF in skin. This may explain why a negative current 
applied at a sensory level can effectively promote the proliferative 
phase of wound healing. In the clinical study by Franek et al.22 
cathodal HVMPC (100 microseconds; 100 pps) was observed to 
improve granulation tissue growth in VLUs. After 2 weeks of 
treatment, the area of granulation tissue in the group receiving SWC 
with compression therapy plus cathodal HVMPC was significantly 
greater than in the control group where only compression therapy and 
SWC were applied (P < .003).  
The authors of the reviews of clinical studies5,43 and of 
epidemiological studies44 point to wound closure as the most 
important endpoint in evaluating the efficacy of wound treatment, but 
in clinical studies with ES, treatment is rarely continued until wounds 
close completely (in only 1 of the reviewed clinical studies were all 
PrUs treated with HVMPC until full closure20), so the percentages of 
wounds that closed after 4, 6, or 12 weeks of treatment are 
frequently reported instead. In trials that end before wounds are 
closed, the PAR of wounds after treatment in relation to baseline is 
crucial,5,43,44 so in the majority of the reviewed studies, the wound 
healing progress is expressed as PAR.20–27 Gilman45,46 has put forward 
a formula (Gilman formula [GF]) for calculating the healing rate for 
wounds of all shapes.  
Aim Of Study  
The aim of this clinical study was to establish whether a 
cathodal HVMPC could improve the healing of chronic PrUs in older 
adults with Stage II and III PrUs.  
Based on research findings previously cited, the authors 
formulated the following research hypothesis: that cathodal HVMPC is 
capable of decreasing PrU surface area regardless of the wound shape 
and can significantly accelerate the healing process.  
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Methods  
A prospective, randomized, double-blind clinical trial was 
conducted with 2 groups of patients to compare the healing of PrUs 
after 6 weeks of intervention involving SWC combined with cathodal 
ES, as well as SWC with sham ES. Ethics approval for the experiment 
was granted from the Academy of Physical Education in Katowice 
Bioethics Commission. The study was registered in Australian New 
Zealand Clinical Trials Registry (ANZCTR12614000207617).  
Participants  
Eligibility  
Patients screened for the trial were hospitalized in 2 nursing 
and care centers. The patient’s eligibility to participate in the study 
was assessed by their physician based on the following criteria: older 
than 60 years, at high risk of PrU development (<14 points on the 
Norton scale), with a PrU of between 1.0 and 50 cm2 and duration 
from 1 to 12 months. In order to make the comparable groups as 
analogous as possible, only individuals with Stage II and III PrUs 
(which are typically diagnosed in older adult patients) located on the 
pelvic girdle (sacrum, coccyx, ischial tuberosity, trochanter major) 
were included in the study.  
The patients who did not qualify for ES (contraindications 
include cancer, electronic implants; malignant, tunneling, and necrotic 
wounds; osteomyelitis; PrU requiring surgical intervention; and metal 
implants in the PrU area) were excluded from participating, as well as 
those with diagnoses that might interfere with wound healing, such as 
diabetes (HbA1c >7%), venous insufficiency, critical infection, 
alcoholism, and allergy to standard wound treatment.  
Demographic Information  
Patient demographics were obtained from standard interviews, 
physical examinations, and the history of concomitant diseases 
contained in the patients’ medical records. Before the study began, 
the Norton scale was used to assess the patients’ physical and mental 
condition, the level of activity, mobility, and incontinence; with the 
Braden scale, the risk of friction and shear, wound moisture, sensory 
perception, physical activity, and mobility were determined. A 
comprehensive review of the patients’ nutrition was also conducted, 
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including the assessment of factors that might influence dietary intake 
and of the extent of nutrient and fluid losses. The nutritional status of 
a patient was quantified by means of the Nutritional Risk Score (NRS 
2002).47  
Wound Severity  
Wound severity at enrollment was established by the physician 
using the National Pressure Ulcer Advisory Panel1 criteria (with Stage 
II PrUs meaning partial-thickness loss of the dermis presenting as a 
shallow open ulcer with a red-pink wound bed, no slough; and Stage 
III PrUs meaning full-thickness tissue loss, subcutaneous fat may be 
visible, but the bone, tendon, or muscle is not exposed).  
Interventions  
Wound Care Program Administered To Both Groups  
Pressure ulcer prevention measures, wound care, and physical 
treatment were administered to all patients using the same 
prospective protocol and under the supervision of the main 
investigator. Each patient was comprehensively assessed by an 
interdisciplinary medical team to develop an individualized wound 
prevention and treatment program consistent with best practices.1,2,48 
The physicians assessed the general condition of the patients and 
their PrUs, as well as developing treatment programs. When 
necessary, neurologists, cardiologists, diabetes specialists, surgeons, 
and other specialists were also consulted. The nurses gave care to the 
patients, administered drugs, and applied dressings to wounds as 
prescribed by the physicians. The physiotherapists created and 
implemented kinesiotherapy programs for the patients. The 
physiotherapists, nurses, and clinical caregivers were responsible for 
applying measures to prevent the development of PrUs, including the 
repositioning of the patients. The dietitians assessed the nutritional 
status of the patients and developed therapies to make up for 
nutritional deficiencies. The clinician caregivers were blinded to study 
group assignments.  
All patients received treatment to prevent the development of 
additional PrUs. Pressure-redistribution surfaces, devices, and pillows 
were provided as needed. Persons who could change position were 
asked to do so as often as possible to relieve pressure on the ulcer 
area. At least once every 2 hours, a nurse, physiotherapist, or clinical 
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caregiver determined whether the patients had changed position. The 
patients who could not move on their own were repositioned by a 
nurse or physiotherapist.  
Blood analysis was performed to screen for nutritional status 
markers and metabolic disorders such as anemia (iron deficiency 
anemia or anemia of chronic disease), thyroid dysfunction, impaired 
glycemic control, dehydration, protein deficit, and hypoalbuminemia.  
The attending physician regularly examined patients’ wounds to 
determine what topical treatments were needed. Intervention 
included tissue debridement, infection and inflammation control, 
maintaining moisture balance, and the monitoring of wound edges 
and the process of epithelialization. Wounds were cleaned with 
antiseptics and then covered with hydrogel or hydrocolloid dressings 
to trigger autolysis. Necrotic tissue was cleaned enzymatically, and 
infected wounds were rinsed with antiseptics. When bacterial infection 
was suspected (presence of fever, leukocytosis, high level of C-
reactive protein, and/or redness and inflammatory infiltration around 
the wound) patients were administered antibiotics. Wounds were 
treated with topical dressings appropriate for the stage of wound 
healing, the depth of the wound, the presence of infection, and the 
presence of exudates, and wound intensity. Cleaned wounds with 
granulation tissue and moderate exudate were covered with dressings 
moistened with 0.9% sodium chloride, hydrocolloid, or polyurethane 
foam dressings. Wounds showing necrotic tissue and wounds with 
considerable exudate were covered with hydrogel dressings or 
alginate dressings. All immobilized patients received low-molecular-
weight heparin as a standard therapy.  
Electrical Stimulation  
In addition to SWC, patients in the ES group and in the control 
group both received active HVMPC and sham HVMPC.  
The HVMPC device was the Intelect Advanced Combo unit 
(model 2771 by Chattanooga Group, Vista, California), which was set 
to generate a twin-peak monophasic pulse (154 microseconds) 
consisting of two 77-microsecond exponential pulses in rapid 
succession. The pulse frequency was 100 pps, and the peak electric 
current was usually 0.24 amperes (A), so it induced only sensory 
perception in the patients without any motor reactions. The voltage 
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was set to 100 V, and the charge delivered by the electrodes was 250 
microcoulombs (µC) per second. This protocol was adopted because 
of the positive results of earlier clinical trials on patients with 
PrUs20,21,26,27 and VLUs.22,24 The patients participated in 5 sessions of 
50 minutes in length per week (Monday through Friday) according to 
the protocols used in other studies.20–22,26,27  
All patients were treated in the same way using identical 
stimulators that had 2 independent circuits for delivering electrical 
current; according to the study protocol, only 1 circuit was active. The 
electrical current parameters (pulse duration and shape, frequency, 
and voltage) and the duration of the procedure were displayed on the 
monitor so that patients in both groups could see them, but in the 
control group, the electrodes were connected to the inactive electrical 
circuit. The person in charge of connecting the electrodes to the 
appropriate circuit (active or passive) was the facility chief 
physiotherapist, who did so in an inconspicuous manner to prevent 
the patient, the physiotherapist in charge of the procedure, and other 
members of the medical team (physicians, nurses, caregivers) from 
knowing whether real or sham ES was applied.  
Each patient was provided with his/her own set of conductive 
carbon-rubber electrodes. The treatment electrode (5.0 × 10.0 cm) 
was placed on an aseptic gauze pad saturated with physiological 
saline overlying the wound site. The return electrode (10.0 × 10.0 
cm) closing the electrical circuit was placed on a gauze pad saturated 
with physiological saline and applied to healthy skin at least 20 cm 
from the PrU.  
Pressure ulcers were stimulated with the cathode during each 
daily treatment period, as in the clinical studies on PrUs21 and VLUs.24 
The preclinical studies36–40 have shown that the cathode can enhance 
fibroblast and epithelial cell motility and stimulate granulation tissue 
growth and reepithelialization.  
Before and after each procedure, the electrodes were sterilized 
in disinfectant solutions (Incidin Liquid and Sani-Cloth Active; Ecolab, 
Monham am Rhein, Germany). The PrUs were thoroughly cleansed 
with a 0.9% sodium chloride solution and covered with the 
aforementioned dressings as soon as the procedure was complete.  
In both groups, the healing of PrUs was monitored for 6 weeks 
or until wounds closed, whichever occurred first. This specific length 
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of observation was imposed by the duration of patient stay in nursing 
and care centers (6 weeks on average).  
In patients with more than 1 PrU, all wounds were treated, but 
only the most severe wound was analyzed statistically.  
Outcomes  
Primary Outcome  
The primary outcome in both groups was percentage reduction 
in WSA in relation to the baseline at week 4 (PAR4) and at week 6 
(PAR6) enabling the comparison of wound healing progress between 
the groups.  
Secondary Outcomes  
The secondary outcomes were as follows:  
1. the value of GF45,46 for comparing wound healing progress 
regardless of wound shape;  
2. average percentage change in wound area by weeks 1 through 
6 of treatment (PAR/week 1, PAR/week 2, PAR/week 3, 
PAR/week 4, PAR/week 5, PAR/week 6), calculated to 
determine in which week WSA decreased the most; and  
3. percentages of PrUs in which WSA closed or increased (relative 
to the baseline), which were calculated after 6 weeks of 
intervention.  
Sample Size  
Group sizes appropriate for the study were established through 
a pilot study. Because results were obtained from the random pilot, 
the sample had unimodal distribution with skewness and flatness 
below 2.5. Thus, the arithmetic average and standard deviation (SD) 
were accepted as reliable measures of central value and dispersion. 
Based on type I error, probability [alpha] = .05 and test power 1 - 
[beta] = .90 were selected. An assumption was made that for wound 
healing progress to be statistically significant the improvement 
against the baseline must be at least 20% in both groups. The groups 
were initially assumed to consist of at least 48 randomly selected 
patients (24 in a group), but to allow for dropouts, 60 participants 
were finally selected.  
  
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Advances in Skin & Wound Care, Vol 29, No. 10 (October 2016): pg. 447-459. DOI. This article is © Wolters Kluwer Health, 
Inc. and permission has been granted for this version to appear in e-Publications@Marquette. Wolters Kluwer Health, 
Inc. does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from Wolters Kluwer Health, Inc. 
14 
 
Randomization/Blinding  
After the included patients, or their legal guardians as 
appropriate, granted their written consents to participate in the 
study, they were randomly allocated between the ES group (SWC 
plus active HVMPC) and the control group (SWC plus sham HVMPC) 
using a concealed process (Figure 1). The allocation procedure did 
not consider who was to receive and when to deliver the treatment.  
 
The randomization schedules were constructed with blocks of 2 
to ensure equal distribution of patients across the 2 groups. The 
allocation sequence was concealed by using sealed envelopes with 
consecutive numbers. After baseline measurements of the patients, 
the main investigator opened the envelopes one at a time in the 
presence of the principal physiotherapist, and the particular patient 
was directed to the indicated group.  
All patients, physicians, care providers, and physiotherapists, as 
well as the person making weekly measurements of WSA and the 
statistician processing the data, were blinded. The only person 
engaged in the experiment who was not blinded was the principal 
physiotherapist, who set the devices to apply active or sham ES.  
Measures and Statistical Methods  
Before the study commenced and at the end of each week of 
treatment, 7 measurements were taken to establish each patient’s 
WSA (in cm2). For all PrUs that closed before the end of week 6, the 
date of closure was recorded. A wound was defined as closed when its 
surface area decreased to 0 cm2.  
The WSA for all patients was measured by a blinded person who 
used the same method as that used in several other clinical 
trials.22,26,27 After the contours of wounds were transferred onto 
transparent film, they were measured with the planimeter to establish 
the WSA. The data obtained were processed by a digitizer (Mutoh 
Kurta XGT; Altek, Liberty Lake, Washington) connected to a personal 
computer (C-GEO version 4.0; Instrumenty Geodezyjne Thadeusz 
Nadowski, Tychy, Poland), which was also used for storing the results.  
Measurement errors arising from different wound shapes 
ranged between 2.7% (for PrUs of 60–70 cm2) and 37.9% (PrUs <1 
cm2). The errors were calculated with the following formula: [DELTA]S 
/ S = I × [DELTA]r / S, where [DELTA]S / S is the relative error of the 
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wound area measurement method; [DELTA]S is the absolute error of 
area measurement; I is a wound perimeter; [DELTA]r is the absolute 
error related to the thickness of the plotting pen (0.2 mm) and to the 
digitizer’s cross-hair (0.1 mm); r = 2 × 0.2 mm + 0.1 mm. A detailed 
discussion of the method used to calculate measurement errors is 
provided in the authors’ earlier study.26  
Both PAR4 and PAR6 were calculated in the following way:  
The GF was:  
The percentage change in wound area at weeks 1 through 6 
were calculated as follows:  
The statistical analysis was performed by a blinded person 
using the Statistica software (version 10.0; StatSoft Polska Sp. z o.o, 
Krakow, Poland). Patient characteristics were checked for normal 
distribution using the Shapiro-Wilk W test. When the distributions 
were found not to be normal, nonparametric tests were applied to 
evaluate the results of the study. The distributions of patient 
characteristics were tested for skewness, kurtosis, and modality. 
Because skewness and kurtosis were in all cases smaller than 4, and 
the distributions were unimodal, a mean and an SD were used to 
measure the central value and dispersion.  
Both comparative groups were tested for the homogeneity of 
patient characteristics using the 2-sided Fisher exact test and the 
Mann-Whitney U test. The Mann-Whitney U test was also used to 
compare mean percentage change in WSA and the values of GF 
between the groups and to establish the statistical significance of 
differences in weekly healing rates between the groups. The 
percentages of PrUs that closed or increased in size were compared 
between the groups after 6 weeks of treatment using the 2-sided 
Fisher exact test. In all cases, the level of significance was set at P 
< .05.  
Results  
Participant Flow  
Between November 1, 2013, and December 30, 2014, 72 
patients were screened for participation in the study. Twelve of those 
patients were not randomized to receive treatment, and 11 of the 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Advances in Skin & Wound Care, Vol 29, No. 10 (October 2016): pg. 447-459. DOI. This article is © Wolters Kluwer Health, 
Inc. and permission has been granted for this version to appear in e-Publications@Marquette. Wolters Kluwer Health, 
Inc. does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express 
permission from Wolters Kluwer Health, Inc. 
16 
 
remaining 60 patients (18.33%) dropped out before the end of the 6-
week treatment period (Figure 1).  
Baseline Data  
Tables 1 and 2 contain the demographic and wound 
characteristics of 49 patients in 2 groups who completed the study. 
There were no statistically significant differences between the groups 
regarding any variable measured at the baseline.  
 
The patients were treated in 2 nursing and care centers that 
strived to prevent the development of PrUs and treated the wounds 
according to the same standards. The sample of patients consisted of 
37 women (75.51%) and 12 men (24.49%) ranging in age from 60 to 
95 years, but mostly older than 80 years (n = 27; 55.1%). All 
patients scored on the Norton scale below 14 points. Thirty-nine 
patients (79.59%) were immobile, or their mobility was very limited. 
Thirty-four patients (69.39%) received a diagnosis of generalized 
atherosclerosis, 19 (38.77%) had type 2 diabetes (HbA1c <7%), and 
19 (38.77%) were affected by a cerebral stroke.  
The patients had a total of 49 PrUs that ranged in size from 
1.18 to 38.34 cm2; 22 PrUs were Stage II (44.9%), and 27 were 
Stage III (55.1%). Of the 49 PrUs, 25 (51.02%) were located in the 
sacral region, 17 (34.69%) on the ischial tuberosity, and 7 (14.28%) 
on the trochanter. Eleven patients (22.45%) had multiple PrUs, and in 
23 patients (46.94%), recurring PrUs were diagnosed. The duration of 
the PrUs before the clinical trial began was 1 to 12 months, with most 
lasting 1 to 3 months (n = 37; 75.51%).  
ES Group  
The ES group consisted of 25 patients, 19 women and 6 men, 
at a mean age of 79.92 years (range, 60–92 years). Two patients 
(8%) were obese (body mass index [BMI], >30 kg/m2), and 4 (16%) 
were underweight (BMI <19 kg/m2). Twenty patients (80%) could not 
change position unless assisted. Sixteen patients (64%) had general 
atherosclerosis, 11 (44%) had diabetes (HbA1c <7%), and 9 (36%) 
were affected by cerebral strokes. This group was diagnosed with a 
total of 25 PrUs, of which 13 (52%) developed in the sacral region, 8 
(32%) on the ischial tuberosity, and 4 (16%) on the trochanter. 
Fourteen PrUs (56%) were Stage III, and 11 (44%) were Stage II. 
Their average duration was 2 months (range, 1–10 months), but most 
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of them (n = 19; 76%) developed less than 3 months before the 
study began. Six patients (24%) had more than 1 PrU, the largest of 
which was monitored for healing.  
Control Group  
The control group consisted of 24 patients, 18 women and 6 
men, at a mean age of 76.33 years (the range was 60–95 years). 
Three patients (12.5%) were obese (BMI >30 kg/m2), and 2 (8.33%) 
were underweight (BMI <19 kg/m2). Twenty patients (80%) needed 
assistance to change position. Eighteen patients (75%) had general 
atherosclerosis, 8 (33.33%) had diabetes (HbA1c <7%), and 10 
(41.67%) were affected by cerebral stroke. These patients had a total 
of 24 PrUs, of which 12 (50%) were located in the sacral region, 9 
(37.5%) on the ischial tuberosity, and 3 (12.5%) on the trochanter. 
Thirteen PrUs (54.17%) were Stage III, and 11 (45.83%) were Stage 
II. Their average duration was 2.81 months (range, 1–12 months), 
but most of them (n = 18; 75%) developed less than 3 months 
before the study commenced. Five patients (20.83%) had more than 
1 PrU, of which the largest was monitored for healing.  
Primary Outcomes  
At week 1 of treatment, the PAR in the ES group was 
statistically significantly greater than that in the control group (35% 
± 30.5% compared with 17.07% ± 34.13% in the control group; P 
= .032). The ES group maintained its advantage over the control 
group for the next 2 weeks (Figure 2). At week 4 of treatment, PAR4 
was greater in the ES group (mean ± SD, 71.64 ± 33.74%) than in 
the control group (44.21 ± 48.58%), but it was not statistically 
significant (P = .064). In the next 2 weeks, wounds healed in both 
groups but at different paces. As a result, PAR6 was significantly 
greater in the ES group (mean ± SD, 80.31 ± 29.02%) than in the 
control group (mean ± SD, 54.65 ± 42.65%) at P = .046 (Figure 2).  
 
Secondary Outcomes  
The GF calculated for the ES group was significantly greater 
(0.95 ± 0.5 compared with 0.57 ± 0.52 in the control group; P 
= .015) (Table 3).  
 
In the ES group, the largest decreases in WSA were observed 
at weeks 1, 2, and 3, by 35%, 32.78%, and 45%, respectively. In 
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the control group, the rates were 17.07%, 12.78%, and 20.32%, 
respectively. At weeks 1 and 2, the differences were statistically 
significant and always in favor of the ES group (P = .032, P = .044) 
(Figure 3).  
The ES group had higher percentages of Stage II and III PrUs 
that closed (respectively, 9 of 11 [45%] and 3 of 14 [17.65%]) than 
the control group (6 of 11 [35.29%] and 1 of 13 [6.25%]), but the 
differences were not statistically significant (at P = .74 and P = .6) 
(Table 3).  
Pressure ulcers did not increase in size in any of the patients 
treated with ES, whereas in the control group, 2 Stage III PrUs were 
larger relative to the baseline (P = .22) (Table 3).  
Discussion  
The results of this clinical trial confirmed the research 
hypothesis that HVMPC accelerates the healing of Stage II through III 
PrUs. Ulcers managed with HVMPC in addition to SWC decreased 
statistically significantly more than those in the control group (SWC 
alone). In all patients, WSA decreased the fastest in the first 4 weeks 
of treatment. In weeks 5 and 6, the surface area of PrUs decreased at 
a slower rate. The PAR was significantly greater in the ES group than 
in the control group in all weeks but week 4. The GF showed that 
regardless of their shape PrUs treated with a combination of SWC and 
HVMPC were decreasing significantly faster than were those receiving 
SWC alone. Unlike the ES group, where not a single PrU increased in 
size, in the control group, 2 Stage III PrUs were larger than at 
baseline. These results are consistent with the results obtained by 
other researchers who treated PrUs with HVMPC.21,22,25–27  
Study patients received a diagnosis of Stage II (44.9%) and III 
PrUs (55.1%). Other investigators applied HVMPC to treat Stage II, 
III, and IV PrUs in spinal cord–injured patients,21,25 older adult 
patients,20,27 and patients immobilized for long periods owing to 
orthopedic injury.26 This study, as well as other studies,21,25–27 
confirms that HVMPC can be effectively applied to treat PrUs.  
Given that patients in this study had comorbid diseases that 
could stimulate the development of new PrUs or interfere with the 
healing of the existing ones, it was not expected that all their wounds 
would close over the 6 weeks of intervention. Accordingly, the 
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percentage decrease in WSA relative to its baseline measurement 
(PAR) was taken as the primary research outcome. Special attention 
was given to PAR4 and PAR6. Percentage area reduction after 4 
weeks is reported by many authors of clinical trials,20–27 and the 
authors of the reviews of clinical studies5,43 and epidemiological 
studies44 consider it a predictor of PrU healing within 12 to 20 weeks. 
Percentage area reduction after 6 weeks was calculated to establish 
the degree of wound healing that could be achieved by applying 
cathodal HVMPC for 6 weeks.  
In 15 randomized controlled trials analyzed by Koel and 
Houghton,5 4 weeks of ES with monophasic electric current decreased 
Stage II-IV PrUs by 37.02% to 69.21%, but in the control groups 
(SWC alone or SWC plus sham ES), the decrease ranged from 6.77% 
to 44.04%. In this study, Stage II and III PrUs treated with HVMPC 
were smaller at week 4 by an average of 71.64% versus 44.21% in 
the control group, so these results are comparable with the results 
reported by Koel and Houghton.5  
Having analyzed retrospectively the effects of topical wound 
care on 306 VLUs and 241 DFUs, Cardinal44 found PAR4 to predict the 
probability of wound closure in 12 weeks. For PAR4 = 37.7%, the 
positive predictive value for complete closure was 70.6%, and the 
likelihood ratio was 6.15, meaning that the odds of total closure in 12 
weeks were 6.15 times greater for wounds with PAR4 of at least 
37.7% than for wounds with smaller PAR4. Considering Cardinal’s44 
results, PAR4 of 71.64% obtained in this study for the ES group 
allows the authors to predict that PrUs would have closed in 12 
weeks.  
In this trial, at week 6 of treatment, the baseline area of Stage 
II and III PrUs in the ES group was smaller by 80.31%. The results of 
other authors who also used HVMPC were very similar. Six weeks of 
HVMPC intervention in Franek et al.26 and Polak et al.27 studies on 26 
Stage II and III PrUs25 and 10 Stage II and III PrUs27 resulted in a 
PAR of 88.9% and 92.67%, respectively. In Kloth and Feedar’s 
study,20 9 Stage IV PrUs healed completely during 7.3 weeks. Griffin 
et al.21 recorded an 80% decrease in Stage II through IV PrUs after 
20 successive days of treatment. Houghton et al.25 who applied 
HVMPC to Stage II through IV PrUs, recorded that they were smaller 
in size by 70.0% at week 12.  
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Wound closure is another important surrogate endpoint in 
clinical trials indicated in reviews.43 The patients treated in this study 
did not stay in the care facilities long enough for the authors to 
observe them until all wounds closed. However, 6 weeks was 
sufficient for 9 of 11 Stage II PrUs (45%) and 3 of 14 Stage III PrUs 
(17.65%) treated with HVMPC + SWC to close. These observations 
suggest that HVMPC must be applied to older adult patients longer 
than 6 weeks for Stage II and III PrUs to close. Houghton et al.25 
noted that 12 weeks of HVMPC + SWC therapy caused all Stage II 
PrUs to close, but only 5 of 15 Stage III through IV PrUs (30%). The 
authors concluded that 12 weeks of intervention with HVMPC + SWC 
was sufficient for Stage II PrUs to close, but in the case of more 
severe PrUs, longer application of ES combined with SWC might be 
necessary to achieve the same result. The study of Houghton et al.25 
does not provide an indication of how long ES should be applied for 
Stage III and IV PrUs to close, as the study was not long enough.  
Methodology of ES with HVMPC  
The HVMPC treatment protocol used in this study was similar to 
that used by other authors.20–27 In all cases, the sterilized treatment 
electrode was placed on the wound, and the return electrode was 
attached to intact periwound skin approximately 15 to 20 cm from the 
wound edge. Both electrodes were separated from tissue by sterile 
gauze pads moistened with physiological saline. These measures 
maintained a moist wound environment and enhanced the flow of 
electric signal through the wound.  
The available literature does not indicate what parameters 
make electric current particularly useful in treating different types of 
soft tissue wounds, but HVMPC in the voltage range from 100 to 150 
V that the authors of this study as well as other authors used to treat 
PrUs,20,21,25–27 VLUs,22,24 and DFUs23 has been demonstrated to be 
effective. The amperage that was selected in this study (0.24 A) 
following other research protocols20–27 caused only sensory sensations 
in the patients, without evoking motor responses from the muscles. 
As in other studies,23–30 the study used the HVMPC twin-peaked 
monophasic pulses of 154 microseconds and a frequency of 100 pps.  
The authors of most studies involving HVMPC applied it to PrUs 
for 45 to 60 minutes, once a day, 5 to 7 days a week, so the total 
duration of ES ranged from 3.75 to 7 hours per week.20–22,24,26,27 The 
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treatment sessions in this study were similar in duration: 50 minutes 
per day, 5 days per week, resulting in a total treatment time per 
week of 4.16 hours.  
Reports from trials indicate that wound healing can be 
enhanced by several current waveforms, but Kloth49 maintains that it 
is the electrical charge energy (charge quantity delivered to the 
wound) that determines the dosage that is the best to promote 
wound healing. According to Kloth’s review of clinical studies,49 ESs 
with LVMPC and HVMPC using an electrical charge of 250 to 500 
µC/second can effectively advance the healing of chronic wounds. 
Some authors of clinical studies have not stated the value of the 
electrical charge they used. They set the charge at the sensory level 
below muscle contraction (visible or palpable) by asking the patients 
about their sensations. In this study, an electrical charge of 250 
µC/second was adopted, the smallest of those recommended for 
wound treatment, because the patients were unable to describe how 
they felt the current. Because of the characteristics of electrical 
impulses, amperage had to be set to 0.24 A so that an electrical 
charge of 250 µC/second could be obtained. In the pretrial tests, an 
amperage of 0.24 A was well tolerated by healthy patients, but larger 
dosages made some complain.  
The application of cathodal stimulation in this study is 
supported by evidence from preclinical studies36–40 and has previously 
been reported by authors treating pressure22 and VLUs.24 Based on a 
review of the results of preclinical and clinical studies, Kloth and 
Zhao30 recommend using cathodal stimulation to improve the healing 
of noninfected wounds as long as regular wound measurements, 
increased granulation, and decreased exudation indicate that wound 
healing is steadily progressing. When wound measurements show that 
healing is not progressing or is regressing, polarity should be changed 
to positive and maintained as long as healing progress continues. If 
healing progress is observed to stop, polarity should be changed 
again and maintained for 7 to 14 treatments as long as healing 
progress is being made. In this study, cathodal HVMPC considerably 
decreased the WSA of PrUs in the first 3 weeks of treatment, by 35%, 
32.78%, and 45.68%, respectively (in the same period, healing rates 
in the control group were 17.07%, 12.78%, and 20.32% a week). In 
the next weeks of cathodal stimulation, WSA continued to decrease, 
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although at a slower rate than in the early stage of treatment. This 
study does not answer the question about whether switching cathodal 
stimulation to anodal after 3 weeks would have enabled PrUs to heal 
as fast. Further clinical research seems necessary to obtain more 
information on this matter.  
The groups of patients in this study were similar at the baseline 
regarding the key determinants of wound healing, such as age, 
wound duration, severity, and initial size. The groups consisted of 
older adult patients (most of whom were >80 years old) at high risk 
of PrU development, who had many comorbid conditions, such as 
systemic atherosclerosis, diabetes, protein deficit, hemoglobin deficit, 
lymphocytes deficit, and so on. Notwithstanding these unfavorable 
circumstances, the applied treatment proved effective. Patients 
receiving ES participated also in an interdisciplinary wound 
management program as recommended by the best practice 
guidelines on PrU treatment.1,2  
Adverse Effects  
Neither in this study nor in the trials conducted by other 
investigators has HVMPC been found to have adverse effects.  
Study Limitations  
Because this study focused on patients with Stage II and III 
PrUs, the results do not predict the outcomes should cathodal HVMPC 
be used to treat Stage IV PrUs.  
The 6-week treatment program (determined by average length 
of patient stay in the facility) was not long enough for all PrUs to heal. 
Consequently, it is not possible to conclude how long HVMPC should 
be applied for Stage II and III PrUs to close. Results enabling the 
evaluation of the long-term efficacy of PrU treatment are not 
presented for several reasons; primarily, after the trial ended some 
patients were discharged and returned to their homes or were 
transferred to other wards to be treated for concomitant diseases.  
The PrU prevention and treatment program was designed for 
both groups based on the same best practice recommendations,2,48 
but particular solutions were adapted to meet the needs of individual 
patients. This customization may have contributed to differences in 
PrU healing between groups.  
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Conclusions  
This research has shown that HVMPC (154 microseconds, 100 
pps, 100 V, 250 µC/second) applied at a sensory level (50 minutes a 
day, 5 times a week) using the cathode as the treatment electrode is 
particularly effective in treating Stage II and III PrUs. This type of ES 
reduced the surface area of Stage II and III PrUs and accelerated 
their healing.  
The results of the study are consistent with those obtained by 
other researchers who have found HVMPC to improve the healing of 
chronic wounds, including PrUs.  
Suggestions for Further Research  
Further RCTs are necessary to establish the efficacy of anodal 
and cathodal HVMPC applied independently and consecutively, as well 
as to determine the optimal parameters of this electric field signal.  
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Image Gallery 
 
Figure 1. Flow Diagram of The Study Process 
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Table 1. Baseline Patient And Wound Characteristics (N = 49) 
 
Table 2. Baseline Characteristics Of Pressure Ulcers (N = 49) 
 
 
Figure 2. Cumulative Percentage Change In Wound Surface Area Calculated After 
Each Week Of Treatment 
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Table 3. Comparison Of Wound Outcomes Between Groups (N = 49) 
 
 
 
Figure 3. Percentage Change In Wound Surface Area Calculated For Each Week Of 
Treatment 
